{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:30Z","timestamp":1787020170975,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CSL Centenary Fellowship"},{"name":"Australian National Health and Medical Research","award":["1194702"],"award-info":[{"award-number":["1194702"]}]},{"name":"Australian National Health and Medical Research","award":["2008501"],"award-info":[{"award-number":["2008501"]}]},{"name":"Australian National Health and Medical Research","award":["1196068"],"award-info":[{"award-number":["1196068"]}]},{"name":"Joint Global Health Trials Scheme","award":["MR\/K007424\/1"],"award-info":[{"award-number":["MR\/K007424\/1"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1054404"],"award-info":[{"award-number":["OPP1054404"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Symptoms reported following the administration of investigational drugs play an important role in decisions for registration and treatment guidelines. However, symptoms are subjective, and interview methods to quantify them are difficult to standardise. We explored differences in symptom reporting across  study sites of a multicentre antimalarial trial, with the aim of informing trial design and the interpretation of safety and tolerability data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data were derived from the IMPROV trial, a randomised, placebo-controlled double blinded trial of high dose primaquine to prevent\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      recurrence conducted in eight study sites in Afghanistan, Ethiopia, Indonesia and Vietnam. At each follow up visit a 13-point symptom questionnaire was completed. The number and percentage of patients with clinically relevant symptoms following the administration of primaquine or placebo, were reported by study site including vomiting, diarrhoea, anorexia, nausea, abdominal pain and dizziness. Multivariable logistic regression was used to estimate the confounder-adjusted site-specific proportion of each symptom.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,336 patients were included. The greatest variation between sites in the proportion of patients reporting symptoms was for anorexia between day 0 and day 13: 97.3% (361\/371) of patients in Arba Minch, Ethiopia, reported the symptom compared with 4.7% (5\/106) of patients in Krong Pa, Vietnam. Differences attenuated slightly after adjusting for treatment arm, age, sex, day 0 parasite density and fever; with the adjusted proportion for anorexia ranging from 4.8% to 97.0%. Differences between sites were greater for symptoms graded as mild or moderate compared to those rated as severe. Differences in symptom reporting were greater between study sites than between treatment arms within the same study site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite standardised training, there was large variation in symptom reporting across trial sites. The reporting of severe symptoms was less skewed compared to mild and moderate symptoms, which are likely to be more subjective. Trialists should clearly distinguish between safety and tolerability outcomes. Differences between trial arms were much less variable across sites, suggesting that the relative difference in reported symptoms between intervention and control group is more relevant than absolute numbers and should be reported when possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov: NCT01814683; March 20\n                      <jats:sup>th<\/jats:sup>\n                      , 2013.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12874-023-02022-3","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:01:59Z","timestamp":1693803719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Kamala","family":"Thriemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert James","family":"Commons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Rajasekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiru Shibiru","family":"Degaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisin","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Hoang","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashenafi","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Nader","family":"Naddim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodhia Pitaloka","family":"Pasaribu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awab Ghulam","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran Tinh","family":"Hien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asrat","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Anwar","family":"Hasanzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenny L.","family":"Ekawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adugna","family":"Woyessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tedla","family":"Teferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Waithira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R. J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kevin","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"von Seidlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"9","key":"2022_CR1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1526-4610.2010.01763.x","volume":"50","author":"RC Coghill","year":"2010","unstructured":"Coghill RC. Individual differences in the subjective experience of pain: new insights into mechanisms and models. Headache. 2010;50(9):1531\u20135.","journal-title":"Headache"},{"issue":"7","key":"2022_CR2","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-011-0031-4","volume":"21","author":"TM Atkinson","year":"2012","unstructured":"Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159\u201364.","journal-title":"Qual Life Res"},{"issue":"4","key":"2022_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1176\/appi.ajp.2008.08070976","volume":"166","author":"DA Brent","year":"2009","unstructured":"Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009;166(4):418\u201326.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2022_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00004714-199202000-00002","volume":"12","author":"JG Rabkin","year":"1992","unstructured":"Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol. 1992;12(1):3\u201310.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2022_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7326\/0003-4819-144-4-200602210-00007","volume":"144","author":"S Bent","year":"2006","unstructured":"Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med. 2006;144(4):257\u201361.","journal-title":"Ann Intern Med"},{"key":"2022_CR6","first-page":"MR000039","volume":"1","author":"EN Allen","year":"2018","unstructured":"Allen EN, Chandler CI, Mandimika N, Leisegang C, Barnes K. Eliciting adverse effects data from participants in clinical trials. Cochrane Database Syst Rev. 2018;1:MR000039.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10202","key":"2022_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","volume":"394","author":"WRJ Taylor","year":"2019","unstructured":"Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394(10202):929\u201338.","journal-title":"Lancet"},{"issue":"1","key":"2022_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12910-018-0259-4","volume":"19","author":"PY Cheah","year":"2018","unstructured":"Cheah PY, Steinkamp N, von Seidlein L, Price RN. The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial. BMC Med Ethics. 2018;19(1):19.","journal-title":"BMC Med Ethics"},{"key":"2022_CR9","unstructured":"WWARN. Malaria Case Record Form CRF 2018 [Available from: https:\/\/www.wwarn.org\/tools-resources\/procedures\/malaria-case-record-form-crf."},{"key":"2022_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12879-015-1276-2","volume":"15","author":"Group IS","year":"2015","unstructured":"Group IS. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infect Dis. 2015;15:558.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"2022_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/204946370800100203","volume":"1","author":"S Peacock","year":"2008","unstructured":"Peacock S, Patel S. Cultural Influences on Pain. Rev Pain. 2008;1(2):6\u20139.","journal-title":"Rev Pain"},{"issue":"2","key":"2022_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0304-3959(01)00408-0","volume":"94","author":"CL Edwards","year":"2001","unstructured":"Edwards CL, Fillingim RB, Keefe F. Race, ethnicity and pain. Pain. 2001;94(2):133\u20137.","journal-title":"Pain"},{"key":"2022_CR13","doi-asserted-by":"crossref","unstructured":"Zborowski M. Cultural components in response to pain. J Soc Issu. 1952;16(30).","DOI":"10.1111\/j.1540-4560.1952.tb01860.x"},{"key":"2022_CR14","first-page":"203","volume":"95","author":"WP Kennedy","year":"1961","unstructured":"Kennedy WP. The nocebo reaction. Med. World. 1961;95:203\u20135.","journal-title":"World"},{"key":"2022_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/1475-2875-12-325","volume":"12","author":"EN Allen","year":"2013","unstructured":"Allen EN, Chandler CI, Mandimika N, Pace C, Mehta U, Barnes KI. Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data. Malar J. 2013;12:325.","journal-title":"Malar J"},{"key":"2022_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1475-2875-7-107","volume":"7","author":"SG Staedke","year":"2008","unstructured":"Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, Maiteki-Sebuguzi C, et al. Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J. 2008;7:107.","journal-title":"Malar J"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-02022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-023-02022-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-02022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T14:14:39Z","timestamp":1700230479000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-023-02022-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1186\/s12874-023-02022-3","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"20 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received full ethical approval from the Human Research Ethics Committee of the Northern Territory Department of Health (HREC), the Oxford Tropical Research Ethics Committee (OxTREC), the Institutional Review Board at the Ministry of Public Health of the Islamic Republic of Afghanistan, the National Research Ethics Review Committee (NRERC) in Ethiopia, the Health Research Ethics Committee of the Faculty of Medicine University of Indonesia and the Ministry of Health Evaluation Committee on Ethics in Biomedical Research in Vietnam. All study activities were carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}